163 related articles for article (PubMed ID: 11805723)
1. Early clinical experience with a novel rapamycin derivative.
Nashan B
Ther Drug Monit; 2002 Feb; 24(1):53-8. PubMed ID: 11805723
[TBL] [Abstract][Full Text] [Related]
2. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.
Hausen B; Ikonen T; Briffa N; Berry GJ; Christians U; Robbins RC; Hook L; Serkova N; Benet LZ; Schuler W; Morris RE
Transplantation; 2000 Jan; 69(1):76-86. PubMed ID: 10653384
[TBL] [Abstract][Full Text] [Related]
3. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine.
Hausen B; Boeke K; Berry GJ; Segarra IT; Christians U; Morris RE
J Heart Lung Transplant; 1999 Feb; 18(2):150-9. PubMed ID: 10194039
[TBL] [Abstract][Full Text] [Related]
4. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation.
Schuurman HJ; Ringers J; Schuler W; Slingerland W; Jonker M
Transplantation; 2000 Mar; 69(5):737-42. PubMed ID: 10755519
[TBL] [Abstract][Full Text] [Related]
5. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
[TBL] [Abstract][Full Text] [Related]
6. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.
Schuler W; Sedrani R; Cottens S; Häberlin B; Schulz M; Schuurman HJ; Zenke G; Zerwes HG; Schreier MH
Transplantation; 1997 Jul; 64(1):36-42. PubMed ID: 9233698
[TBL] [Abstract][Full Text] [Related]
7. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine.
Schuurman HJ; Cottens S; Fuchs S; Joergensen J; Meerloo T; Sedrani R; Tanner M; Zenke G; Schuler W
Transplantation; 1997 Jul; 64(1):32-5. PubMed ID: 9233697
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.
Hausen B; Boeke K; Berry GJ; Christians U; Schüler W; Morris RE
Ann Thorac Surg; 2000 Mar; 69(3):904-9. PubMed ID: 10750781
[TBL] [Abstract][Full Text] [Related]
9. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts.
Viklický O; Zou H; Müller V; Lacha J; Szabó A; Heemann U
Transplantation; 2000 Feb; 69(4):497-502. PubMed ID: 10708101
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
11. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
Kahan BD; Kaplan B; Lorber MI; Winkler M; Cambon N; Boger RS
Transplantation; 2001 May; 71(10):1400-6. PubMed ID: 11391226
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
13. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
14. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
Pascual J
Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.
Hausen B; Boeke K; Berry GJ; Segarra I; Benet LZ; Christians U; Morris RE
Transplantation; 1999 Apr; 67(7):956-62. PubMed ID: 10221478
[TBL] [Abstract][Full Text] [Related]
16. Review of the proliferation inhibitor everolimus.
Nashan B
Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SDZ RAD compared with CsA monotherapyand combined Rad/FTY720 treatment in a murine cardiac allotransplantation model.
Nikolova Z; Hof A; Baumlin Y; Hof RP
Transpl Immunol; 2001 Oct; 9(1):43-9. PubMed ID: 11680571
[TBL] [Abstract][Full Text] [Related]
19. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.
Serkova N; Hausen B; Berry GJ; Jacobsen W; Benet LZ; Morris RE; Christians U
J Pharmacol Exp Ther; 2000 Jul; 294(1):323-32. PubMed ID: 10871329
[TBL] [Abstract][Full Text] [Related]
20. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.
Neumayer HH
Transplantation; 2005 May; 79(9 Suppl):S72-5. PubMed ID: 15880019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
